These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33718255)

  • 1. Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves' Orbitopathy: A Prospective Trial.
    Hoppe E; Lee ACH; Hoppe D; Kahaly GJ
    Eur Thyroid J; 2021 Feb; 9(6):313-320. PubMed ID: 33718255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of quality of life in patients with Graves orbitopathy and its influencing factors].
    Weng CY; Li ZF; Hu SD; Luo YS; Feng XT; Zhong Q; Zhang Q; Shen J
    Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):577-583. PubMed ID: 31365979
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients.
    Villagelin D; Romaldini J; Andrade J; Santos R; Milkos A; Teixeira PFDS; Ward LS
    Front Endocrinol (Lausanne); 2019; 10():192. PubMed ID: 31024443
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of disease-specific quality of life and its influencing factors in Bulgarian patients with Graves' orbitopathy.
    Stoynova MA; Shinkov AD; Dimitrova ID; Yankova IA; Kovatcheva RD
    Int Ophthalmol; 2024 Feb; 44(1):68. PubMed ID: 38347322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
    Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
    Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Graves' Orbitopathy-Specific Quality of Life Questionnaire in the Mainland Chinese Population.
    Zeng P; Fan SX; Li ZJ; Peng YY; Hu YX; Xu MT; Wang M
    J Ophthalmol; 2019; 2019():7602419. PubMed ID: 31011452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
    Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
    Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective and subjective outcomes of strabismus surgery in Graves' orbitopathy: a prospective multicentre study.
    Jellema HM; Saeed P; Mombaerts I; Dolman PJ; Garrity J; Kazim M; Dhrami-Gavazi E; Lyons C; Nieuwkerk P; Mourits MP
    Acta Ophthalmol; 2017 Jun; 95(4):386-391. PubMed ID: 28133945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Ophthalmic Surgery for Graves' Orbitopathy on Quality of Life: A Systematic Review and Meta-Analysis.
    Woo T; Li C; Ganesananthan S; Rajendram R; Uddin J; Lee RWJ; Dayan C; Taylor P
    Thyroid; 2022 Feb; 32(2):177-187. PubMed ID: 34877883
    [No Abstract]   [Full Text] [Related]  

  • 10. Quality of life of patients with thyroid eye disease: 3-year follow-up in a multidisciplinary clinic in Israel.
    Zloto O; Sagiv O; Priel A; Cukierman-Yaffe T; Tirosh A; Agmon-Levin N; Madgar S; Serlin T; Ben Simon G
    Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):2009-2015. PubMed ID: 33528651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GO-QOL--disease-specific quality of life questionnaire in Graves' orbitopathy.
    Sawicka-Gutaj N; Bednarczuk T; Daroszewski J; Waligórska-Stachura J; Miśkiewicz P; Sowiński J; Bolanowski M; Ruchała M
    Endokrynol Pol; 2015; 66(4):362-6. PubMed ID: 26323474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the quality of life in Indian Graves' orbitopathy patients and validation of Hindi version of GO-QOL questionnaire.
    Delampady K; Reddy SVB; Yadav SB
    Indian J Ophthalmol; 2020 Aug; 68(8):1617-1621. PubMed ID: 32709791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).
    Schuh A; Ayvaz G; Baldeschi L; Baretić M; Bechtold D; Boschi A; Brix TH; Burlacu MC; Ciric J; Covelli D; Currò N; Donati S; Eckstein AK; Fichter N; Führer D; Horn M; Jabłońska-Pawlak A; Juri Mandić J; Kahaly GJ; Konuk O; Langbein A; Lanzolla G; Marcocci C; Marinò M; Miśkiewicz P; Beleslin BN; Pérez-Lázaro A; Pérez-López M; Ponto KA; Quinn A; Rudofsky G; Salvi M; Schittkowski MP; Tanda ML; Toruner F; Vaidya B; Hintschich CR
    Br J Ophthalmol; 2024 Jan; 108(2):294-300. PubMed ID: 36627174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
    Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
    Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.
    Bartalena L; Baldeschi L; Boboridis K; Eckstein A; Kahaly GJ; Marcocci C; Perros P; Salvi M; Wiersinga WM;
    Eur Thyroid J; 2016 Mar; 5(1):9-26. PubMed ID: 27099835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.
    Perros P; Žarković M; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi A; Bournaud C; Brix TH; Covelli D; Ćirić S; Daumerie C; Eckstein A; Fichter N; Führer D; Hegedüs L; Kahaly GJ; Konuk O; Lareida J; Lazarus J; Leo M; Mathiopoulou L; Menconi F; Morris D; Okosieme O; Orgiazzi J; Pitz S; Salvi M; Vardanian-Vartin C; Wiersinga W; Bernard M; Clarke L; Currò N; Dayan C; Dickinson J; Knežević M; Lane C; Marcocci C; Marinò M; Möller L; Nardi M; Neoh C; Pearce S; von Arx G; Törüner FB
    Br J Ophthalmol; 2015 Nov; 99(11):1531-5. PubMed ID: 25953846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
    Tanda ML; Piantanida E; Liparulo L; Veronesi G; Lai A; Sassi L; Pariani N; Gallo D; Azzolini C; Ferrario M; Bartalena L
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1443-9. PubMed ID: 23408569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in a german graves orbitopathy population.
    Ponto KA; Hommel G; Pitz S; Elflein H; Pfeiffer N; Kahaly GJ
    Am J Ophthalmol; 2011 Sep; 152(3):483-490.e1. PubMed ID: 21676374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.
    Kahaly GJ; Pitz S; Hommel G; Dittmar M
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5234-40. PubMed ID: 15998777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.